Developments in NDMM

+ - Poll Question 1 Click to collapse

Based on these findings, what is the R-ISS stage for this patient?

A. R-ISS Stage 1

B. R-ISS Stage 1a

C. R-ISS Stage 2

D. R-ISS Stage 2a

E. R-ISS Stage 3

F. R-ISS Stage 3a

Submit

+ - Poll Question 2 Click to collapse

Based on his risk level, please select your induction treatment of choice.

A. Rd

B. VCd

C. RVd

D. KRd

E. RVd + daratumumab

F. KRd +daratumumab

Submit

+ - Poll Question 3 Click to collapse

At this point in treatment, what would you recommend?

A. Recommend stem cell collection and transplant

B. Recommend stem cell collection and delay transplant

C. Continue treatment and not consider transplant

D. Refer for allogeneic transplant due to the patient age

Submit

+ - Poll Question 4 Click to collapse

Based on these findings, what is the R-ISS stage for this patient?

A. ISS Stage 3

B. R-ISS Stage 1

C. ISS Stage 1

D. R-ISS Stage 2

E. R-ISS Stage 3

Submit

+ - Poll Question 5 Click to collapse

What would you choose as the best treatment option at this time?

A. Rd

B. MPV

C. MPT

D. VRd

E. DRd

F. KRd

G. VRd + daratumumab

Submit

+ - Poll Question 6 Click to collapse

Based on the MAIA trial, what would be the best response to her question?

A. Continue with the treatment for 12 months then stop

B. Continue with treatment until reaching CR, go 2 cycles beyond and then stop

C. Continue with lenalidomide until progression

D. Continue with lenalidomide and the daratumumab until progression

Submit

Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes

MediCom Worldwide, Inc. Links